RxDoctor Payments Data

Trisha Overvaag

Psychiatric/Mental Health · Mesa, AZNPI 1215546155

Payments from drug & device makers

$1,388in general payments, 2019–2025

Across 79 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$222
  • AbbVie$201
  • Otsuka America Pharmaceutical, Inc.$168
  • Johnson & Johnson$167
  • Neurocrine Biosciences, Inc.$114
  • Alkermes, Inc.$100
  • plus $415 from 10 others

What the payments were for

  • Food & beverage$1,388100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,388 in reported general payments places this provider in the 70th percentile of 1,230 psychiatric/mental health providers in Arizona.

See all psychiatric/mental health providers in Arizona

Medicare billing

Part B allowed, 2024
$3,118
Medicare patients
11
Services billed
46

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl27$40,886
DayvigoLemborexant12$3,874
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl15$2,845
Atomoxetine Hcl13$918
Quetiapine Fumarate70$861
Lurasidone Hcl11$671
Gabapentin45$566
Hydroxyzine Pamoate29$518
Bupropion XlBupropion Hcl13$477
Aripiprazole13$451
Lamotrigine52$439
Zolpidem Tartrate16$401
Prazosin Hcl16$393
Trazodone Hcl43$379
Buspirone Hcl27$372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$201$40,88627 claims
Eisai Inc.Dayvigo$17$3,87412 claims
Almatica Pharma LLCSertraline Hcl$53$7330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,230 psychiatric/mental health providers in Arizona.

Other psychiatric/mental health in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →